Bright Minds Biosciences Inc.
DRUG
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 103.26% | 82.59% | 74.68% | 30.44% | -24.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 643.94% | 1,315.68% | 549.12% | -5.44% | -51.35% |
| Operating Income | -643.94% | -1,315.68% | -549.12% | 5.44% | 51.35% |
| Income Before Tax | -423.06% | -2,355.60% | -382.70% | 102.86% | 50.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -423.06% | -2,355.60% | -382.70% | 102.86% | 50.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -423.06% | -2,355.60% | -382.70% | 102.86% | 50.22% |
| EBIT | -643.94% | -1,315.68% | -549.12% | 5.44% | 51.35% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -223.68% | -1,522.61% | -206.18% | 101.77% | 58.05% |
| Normalized Basic EPS | -223.61% | -1,522.55% | -206.21% | 101.79% | 58.03% |
| EPS Diluted | -226.20% | -1,565.48% | -203.53% | 101.76% | 58.05% |
| Normalized Diluted EPS | -223.61% | -1,522.55% | -206.21% | 101.64% | 58.03% |
| Average Basic Shares Outstanding | 61.65% | 58.70% | 57.68% | 60.45% | 18.62% |
| Average Diluted Shares Outstanding | 61.65% | 58.70% | 57.68% | 72.84% | 18.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |